Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
10(40%)
Results Posted
88%(7 trials)
Terminated
2(8%)

Phase Distribution

Ph phase_2
18
72%
Ph phase_4
1
4%
Ph phase_1
4
16%
Ph not_applicable
1
4%

Phase Distribution

4

Early Stage

18

Mid Stage

1

Late Stage

Phase Distribution24 total trials
Phase 1Safety & dosage
4(16.7%)
Phase 2Efficacy & side effects
18(75.0%)
Phase 4Post-market surveillance
1(4.2%)
N/ANon-phased studies
1(4.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

8 of 12 finished

Non-Completion Rate

33.3%

4 ended early

Currently Active

10

trials recruiting

Total Trials

25

all time

Status Distribution
Active(12)
Completed(8)
Terminated(4)
Other(1)

Detailed Status

Recruiting8
Completed8
Active, not recruiting2
Withdrawn2
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
10
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (16.7%)
Phase 218 (75.0%)
Phase 41 (4.2%)
N/A1 (4.2%)

Trials by Status

active_not_recruiting28%
recruiting832%
completed832%
unknown14%
withdrawn28%
not_yet_recruiting14%
terminated28%
enrolling_by_invitation14%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT06305598Phase 1

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Recruiting
NCT04895306Phase 2

Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)

Completed
NCT07142551Phase 2

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Recruiting
NCT07278362Phase 4

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

Not Yet Recruiting
NCT04558866Phase 2

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)

Active Not Recruiting
NCT04731376Phase 1

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Active Not Recruiting
NCT06039371Phase 2

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Recruiting
NCT06059118Phase 2

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Recruiting
NCT06100705Phase 2

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

Recruiting
NCT03516812Phase 2

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

Completed
NCT06922318Phase 2

The COSMYC Trial (COmbined Suppression of MYC)

Recruiting
NCT04363164Phase 2

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Recruiting
NCT06111209Phase 2

The Anabolic Effect of Testosterone on Pelvic Floor Muscles

Recruiting
NCT03554317Phase 2

COMbination of Bipolar Androgen Therapy and Nivolumab

Completed
NCT02995330Phase 1

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Terminated
NCT04551144

Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors

Terminated
NCT04424654Phase 2

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy

Completed
NCT02090114Phase 2

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

Completed
NCT04345666Phase 2

Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
25